

By: Representative Yancey

To: Drug Policy

HOUSE BILL NO. 813
(As Passed the House)

1 AN ACT TO CREATE THE "MISSISSIPPI STUDY ON THE AFFORDABILITY
2 OF INSULIN ACT"; TO REQUIRE THE STATE HEALTH OFFICER OF THE
3 MISSISSIPPI STATE DEPARTMENT OF HEALTH TO CONDUCT A STUDY THAT
4 EXAMINES CERTAIN INFORMATION REGARDING DIABETES AND SUBMIT TO THE
5 CHAIRMEN OF BOTH THE HOUSE AND SENATE DRUG POLICY COMMITTEES A
6 REPORT ON SUCH STUDY BY NO LATER THAN DECEMBER 31, 2022; AND FOR
7 RELATED PURPOSES.

8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

9 **SECTION 1.** This act shall be known and may be cited as the
10 "Mississippi Study on the Affordability of Insulin Act."

11 **SECTION 2.** The State Health Officer of the Mississippi State
12 Department of Health shall:

- 13 (a) Conduct a study that examines:
 - 14 (i) For each type or classification of diabetes,
 - 15 including Type 1 diabetes, Type 2 diabetes, gestational diabetes
 - 16 and other conditions causing reliance on insulin, the effect of
 - 17 the affordability of insulin on:
 - 18 1. Adherence to insulin prescriptions;
 - 19 2. Rates of diabetic ketoacidosis;



20 3. Downstream impacts of insulin adherence
21 including rates of dialysis treatment and end-stage renal disease;

22 4. Spending by state health programs in acute
23 episodes that could have been averted by adhering to an insulin
24 prescription; and

25 5. Other factors, as appropriate, to
26 understand the impacts of insulin affordability on health outcomes
27 and insured and uninsured individuals with diabetes.

28 (ii) Among the individuals who are unable to
29 afford insulin, the numbers of such individuals:

30 1. Who are uninsured;

31 2. Who are covered under private health
32 insurance; and

33 3. Who are covered under public health
34 insurance programs; and

35 (b) By no later than December 31, 2022, submit to the
36 chairman of the House Drug Policy Committee and the chairman of
37 the Senate Drug Policy Committee a report on the Mississippi Study
38 on the Affordability of Insulin.

39 **SECTION 3.** This act shall take effect and be in force from
40 and after July 1, 2022.

